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Chromium treatment of depression
Malcolm N. McLeod and Robert N. Golden
Department of Psychiatry, University of North Carolina School of Medicine, Chapel Hill, NC 27599–7160, USA
Abstract
Eight patients with refractory mood disorders received chromium supplements and described dramatic
improvements in their symptoms and functioning. In several instances, single-blind trials confirmed specificity
of response to chromium. Side-effects were rare and mild, and most commonly included enhanced dreaming
and mild psychomotor activation. To our knowledge, this is the first case series describing the response to
chromium monotherapy. The putative antidepressant effects of chromium could be accounted for by
enhancement of insulin utilization and related increases in tryptophan availability in the central nervous system,
and}or by chromium’s effects on norepinephrine release.
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Introduction
Chromium is a trace element which appears to affect
monoamine neurotransmitter systems (Horacek et al.,
1999 ; Liu and Lin, 1997). Recently, we described a series
of patients with refractory dysthymic disorder who
responded to chromium potentiation of antidepressant
pharmacotherapy (McLeod et al., 1999). We now report
the effect of chromium alone in a series of 8 patients with
refractory mood disorders. Case summaries for 3 of the
patients are presented below; the remaining cases are
outlined in Table 1 (case reports are available on request).
To our knowledge, this is the first description of chromium
monotherapy in the treatment of depression.
Case reports
Case 1
Mr A developed bipolar II disorder with the onset of a
major depressive episode in his late 20s. On lithium
prophylaxis, his mood stabilized, although he continued
to experience periods of irritability. He attributed feelings
of being ‘ slowed down’ and a 30-lb weight gain to
lithium, and he experienced breakthrough depressions,
usually during autumn. Various antidepressants, including
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amitriptyline and sertraline, provoked unacceptable side-
effects.
Within 2 d of commencing a trial with 400 µg}d
chromium, the patient reported feeling more relaxed and
stable than he ever had since the onset of his bipolar
disorder, and his wife noticed a change in his ‘ attitude ’.
Soon, the patient decided to discontinue the lithium and
continue with chromium alone, he then began to feel more
energetic, more stable, and less hungry (and gradually lost
23 lb).
Several months later, he forgot to take his chromium,
and within a few days his symptoms returned. In order to
‘ catch up ’, he took 800 µg}d and developed diaphoresis
each morning and a mild hand tremor. After reducing the
dosage to 600 µg}d he again went into complete
remission and he has now been symptom-free for 17
months. After more than 1 yr of chromium treatment, he
developed uric acid kidney stones. One year after
switching to a different chromium preparation, there has
been no recurrence of kidney stones.
Case 2
Mr B sought treatment for a major depressive episode of
5 yr duration. He met DSM-IV criteria for bipolar II
disorder, with current symptoms of depressed mood,
crying spells, hypersomnia, carbohydrate craving with a
weight gain of 25 lb in the past year, diminished ability to
concentrate, fatigue, and suicidal ideation.
Treatment with sertraline led to improvement in his
mood, but he quickly developed unacceptable sexual side-
effects. Following a discussion of the limited available
information regarding chromium pharmacotherapy, the
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Table 1. Case summaries
Case Age Gender Diagnosis Outcome
1 50 M BP II with seasonal pattern Response to 600 µg}d ; symptom-free for 17­
months ; tremor on 800 µg}d
2 38 M BP II Response to 600 µg}d
3 47 M Dysthymic disorder Response to 400 µg}d*
4 47 M Depressive disorder not otherwise
specified with seasonal pattern
Response to 400 µg}d* ; chromium stopped after
4 months ; remains in remission after 16 months
5 50 M Dysthymic disorder Response to 600 µg}d
6 62 M Major depressive disorder and
adult onset diabetes
Response to 400 µg}d ; improvement in stabilization
of blood glucose levels
7 43 F Major depressive disorder Response to 400 µg}d*
8 50 F Dysthymic disorder Response to 500 µg}d
* Participated in a single-blind controlled trial.
after his first dose, he reported experiencing unusually
vivid and intense dreams and the beginning of an
improvement in his mood. His mood continued to
improve, but his carbohydrate craving persisted. After the
dose of his chromium was increased to 600 µg}d, his
intense craving for food disappeared, and he noticed an
unmistakable increase in his energy level, improvement in
his concentration and cognition, and normalization in his
sleep. By his self-report, his functioning improved from a
baseline level of 50 on the GAF scale to 85. Because of
intermittent brief dizzy spells, he was examined by a
neurologist, who made the diagnosis of orthostatic
hypotension. After switching from chromium poly-
nicotinate to chromium picolinate, the dizzy spells have
not returned, and he continues to enjoy sustained relief
from the symptoms.
Case 3
Mr C suffered from dysthymic disorder, as well as
intermittent panic attacks and rage outbursts, since early
adulthood. In his early 30s, he entered psychoanalysis,
which helped him ‘control the damage ’ that resulted from
the rage outbursts, but did not alleviate his mood disorder.
His family physician prescribed antidepressants, but
because of cognitive side-effects, the patient refused to
consider additional antidepressant treatments.
As an alternative, Mr C agreed to a supervised trial
of chromium. The first night after commencing with
400 µg}d he experienced strikingly vivid dreams, and
over the next several days there was a dramatic
improvement in his mood and behaviour. He became
much less withdrawn, and enjoyed interactions with
colleagues at work to a greater extent than at any time
during the previous decades.
After 7 wk of sustained improvement, the patient
consented to a trial of single-blind substitution of other
ingredients, in order to rule out a placebo effect. After
taking vitamin B12 tablets that were almost identical in
appearance to the chromium picolinate for 1 wk, he
reported that he was ‘hungry, tired, had no interest in sex,
and was worrying about everything ’. The second week of
the trial he received oyster shell calcium, and at the end of
that week he described feeling sad, anxious, fatigued,
hopeless, and hungry, with a substantial sleep disturbance.
During the third week of the trial, after receiving a
preparation of chromium polynicotinate that was different
in appearance from the prior formulation, he reported
an immediate response, with remission of all of his
symptoms. This dramatic improvement has now lasted 16
months.
Discussion
Our 8 patients experienced striking clinical responses to
chromium monotherapy for chronic, refractory mood
disorders, which had been present for years, and had failed
to respond to multiple clinical interventions. All of the
patients experienced clinical remissions, which enabled
them to return to more productive levels of functioning
without any significant depressive symptoms. The
patients were not a homogeneous group (see Table 1),
and included individuals with bipolar II disorder (case nos.
1 and 2), dysthymic disorder (case nos. 3, 5, 8), major
depression (case nos. 6, 7), and ‘minor ’ depression (i.e.
depressive disorder not otherwise specified, case no. 4),
with seasonal pattern in a few instances (case nos. 1, 4).
There were some common features, however. Most of the
patients described carbohydrate craving, even in the
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this context, it is interesting to note that chromium has
well-described effects on carbohydrate metabolism, and
increases the efficiency of insulin utilization (Anderson et
al., 1997). In fact, case no. 6 experienced improvement in
his adult onset diabetes while on chromium. Thus, the
dramatic impact of chromium in normalizing appetite in
these patients may be linked to this particular biological
effect, which in turn may offer a clue to the mechanism of
action for chromium’s putative antidepressant activity.
There appears to be a relationship between peripheral
insulin sensitivity and central serotonergic activity. De-
pressed patients show poor utilization of glucose in
glucose tolerance tests (Wright et al., 1976), and a
decreased hypoglycaemic response to insulin (Casper et
al., 1977 ; Wright et al., 1976). Recently, Horacek et al.
(1999) demonstrated a relationship between sensitivity
to insulin and central serotonergic activity in healthy
volunteers, using the hyperinsulinaemic–euglycaemic
clamp technique and d-fenfluramine challenge. Chrom-
ium’s powerful effect in increasing insulin sensitivity
could then enhance insulin-mediated increases in trypto-
phan availability and transport across the blood–brain
barrier (Fukagawa et al., 1986 ; Jamnicky et al., 1991)
and consequent serotonin synthesis (Fernstrom, 1976).
Such a mechanism could account for the very rapid
changes observed in these patients when chromium
therapy was discontinued and initiated, since tryptophan
depletion and replenishment can stimulate very rapid
changes in mood and other symptoms in depressed
patients. Alternatively, chromium’s effects in these
patients could be mediated via its enhancement of
norepinephrine release (Liu and Lin, 1997).
Uncontrolled case reports of a putative new treatment
raise the question of placebo effect. The remarkably rapid
onset of clinical response, and the rapid relapse when
chromium treatment was interrupted, is not characteristic
of established antidepressants or mood stabilizing agents,
and is suggestive of a placebo response (although it could
also be explained on the basis of very rapid changes in
tryptophan availability as described above). However,
several aspects of these cases do not support a placebo
response. Each of the patients had a chronic mood
disorder, andmost had failed to respond to prior treatment
trials. In three instances (case nos. 3, 4, 7), single-blind
trials were employed, and confirmed specificity of the
chromium response. The almost uniform, spontaneous
description of vivid dreaming after the onset of chromium
treatment suggests that chromium exerts central nervous
effects. Finally, the sustained remission in previously
refractory patients is not typical of a placebo response.
Chromium dietary supplements are considered to be
safe, especially in oral formulations within the dosage
range for these patients (Duncan, 1999). However, it
should be noted that one of the patients (case no. 1)
experienced an adverse event while taking a chromium
preparation (the development of uric acid renal stones),
although a cause-and-effect relationship was not clearly
established [see Duncan (1999), for a review of the safety
of chromium use and renal disease]. Several patients
described mild psychomotor activation while taking
chromium, including tremor and a ‘ caffeine-like effect ’,
and most experienced vivid dreaming. Three patients
experienced an unpleasant flushing sensation and ortho-
static hypotension while taking chromium polynicotinate
but not chromium picolinate.
This preliminary report raises some important
questions : (1) ‘ Is chromium in fact an effective and safe
antidepressant ? ’ (2) ‘Like lithium, does it possess mood
stabilizing properties, as well as antidepressant effects ? ’
(3) ‘What is the optimal dose range, and is there a
relationship between plasma levels and therapeutic and}
or side-effects ? ’ Based on the dramatic and sustained
responses that these patients experienced, we believe that
further study, including prospective, double-blind con-
trolled trials, is clearly warranted.
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